Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Argatroban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 7/20 | 0.83 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.78 |
| ▸ | F10 | P00742 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | PLAT | P00750 | 1/20 | 0.78 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.78 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Argatroban SCHEMBL1145308 | 1.00 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL1145427 | 1.00 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL4308143 | 1.00 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL6852675 | 1.00 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL3175687 | 1.00 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL4933701 | 1.00 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL1817517 | 1.00 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL29572887 | 1.00 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL23356536 | 0.99 | F2 (0.82) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL3145300 | 0.99 | F2 (0.82) | F2PRSS1F10LMNAPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23614 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120771360-B | Composite anticoagulation coating and preparation method and application thereof | Nanjing Hanke Mingde Medical Technology Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| US-12623010-B2 | Blood oxygenator with an organic membrane | UNIWERSYTET SLASKI (PL) | 2026-05-12 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12605371-B2 | Combination therapy for cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-04-21 | — | — | US | claimed |
| US-20260097063-A1 | ANTI-C5 ANTIBODY/C5 IRNA DOSING REGIMENS FOR TREATING C5-ASSOCIATED DISEASES | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | claimed |
| US-20260083773-A1 | PEGYLATED MENAQUINOL COMPOSITIONS AND METHODS OF TREATMENT | EPIZON PHARMA INC (US) | 2026-03-26 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-12568959-B2 | Organ preservation and/or perfusion solution | XVIVO PERFUSION AB (SE) | 2026-03-10 | — | — | US | claimed |
| US-20260053804-A1 | Compositions and Methods for the Restoration of Ciliary Function | UNIV YALE (US) | 2026-02-26 | — | — | US | claimed |
| US-20260048181-A1 | ANTIMICROBIAL POLYCARBONATE COATINGS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-02-19 | — | — | US | claimed |
| WO-1995023811-A1 | NOVEL CARBOCYCLIC COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION BY INTERACTION WITH THE GPIIB/IIIA RECEPTOR COMPLEX | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-09-08 | — | — | WO | claimed |
| EP-0669131-A1 | Aquous concentrated solutions containing argatroban | SYNTHELABO (FR) | 1995-08-30 | — | — | EP | claimed |
| US-5433940-A | Synthetic molecules mimic action of hirudin by binding to both the low affinity anion-binding exosite and the catalytic site of thrombin | BIOGEN, INC. (US) | 1995-07-18 | — | — | US | claimed |
| WO-1994022910-A1 | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | claimed |
| CN-1087015-A | Utilize the direct inhibitor manufacturing of thrombin to have the active medicine of thrombus | SYNTHELABO (FR) | 1994-05-25 | — | — | CN | claimed |
| EP-0565897-A1 | Argatroban preparations for ophthalmic use | Mitsubishi Chemical Corporation (JP) | 1993-10-20 | — | — | EP | claimed |
| US-5196404-A | Hirudin mimic, polypeptide, hirulog; bivalirudin FDA Orange book listed patent | BIOGEN, INC. (US) | 1993-03-23 | — | — | US | claimed |
| EP-0504257-A4 | (ALA IL-8) 77 AS A LEUKOCYTE ADHESION INHIBITOR | — | 1993-03-03 | — | — | EP | claimed |
| EP-0504257-A1 | [Ala IL-8] 77 AS A LEUKOCYTE ADHESION INHIBITOR | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1992-09-23 | — | — | EP | claimed |
| WO-1991008231-A1 | [Ala IL-8]77 AS A LEUKOCYTE ADHESION INHIBITOR | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1991-06-13 | — | — | WO | claimed |